https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accounts-payable https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accounts-receivable https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accrued-employee-benefits-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accrued-liabilities-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accrued-marketing-costs-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accumulated-depreciation https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accumulated-oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/accumulated-oci-foreign-currency-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/acquired-finite-lived-intangible-asset-residual-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/acquired-noncurrent-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-liability https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-liability-1 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/acquisition-contingent-consideration-liability https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/acquisitions https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/advertising-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/allowance-for-doubtful-accounts-receivable https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/allowance-for-doubtful-accounts-receivable-change https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/allowance-for-doubtful-accounts-receivable-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/amended-reports-10-k https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/amended-reports-10-q https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/amortization https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/amortization-of-acquired-intangible-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/aoci https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/area-of-real-estate-property https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/assets-fair-value-disclosure https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/available-for-sale-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/available-for-sale-fair-value-disclosure https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/available-for-sale-gross-realized-gain-loss-excluding-other-than-temporary-impairments https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/available-for-sale-unrealized-loss-position-12-months-or-longer-aggregate-losses https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/basic-shares https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-contingent-consideration-at-fair-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-contingent-consideration-at-fair-value-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-contingent-consideration-at-fair-value-noncurrent https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-contingent-consideration-potential-cash-payment https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-cost-of-acquired-entity-cash-paid https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-cost-of-acquired-entity-equity-interests-issued-and-issuable https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-cost-of-acquired-entity-purchase-price https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-cost-of-acquired-entity-transaction-costs https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-pro-forma-earnings-per-share-basic https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-pro-forma-earnings-per-share-diluted https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-current-assets-cash-and-cash-equivalents https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-current-assets-inventory https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-current-assets-prepaid-expense-and-other-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-current-assets-receivables https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-current-liabilities-other-liabilities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-deferred-tax-assets-noncurrent https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-goodwill-amount https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-intangible-assets-other-than-goodwill https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisition-purchase-price-allocation-property-plant-and-equipment https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisitions-pro-forma-net-income-loss https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/business-acquisitions-pro-forma-revenue https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/buyback-authorization https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/buyback-authorization-remaining https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/buybacks-share-repurchases https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/buybacks-shares-repurchased https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/buybacks-stock-repurchased-shares https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/buybacks-stock-repurchased-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/capital-expenditures https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/cash-and-equivalents https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/cash-flow-breakdown https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/certificates-of-deposit-at-carrying-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/common-stock-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/comprehensive-income https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/concentration-risk-percentage https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/cost-of-revenue https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/costs-and-expenses https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/cumulative-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/current-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/current-liabilities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/damages-awarded-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/debt-basis-spread-on-variable-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/debt-face-amount https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/debt-interest-rate-stated-percentage https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-revenue https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-liabilities-net-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-liabilities-net-noncurrent https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-net https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-net-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-net-noncurrent https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-domestic https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-state-and-local https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-liabilities-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/deferred-tax-liabilities-other https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/defined-contribution-plan-employer-discretionary-contribution-amount https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/depreciation https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/diluted-shares https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/dilutive-shares https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/entity-number-of-employees https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/entity-wide-revenue-major-customer-percentage https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/eps https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/eps-basic https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/escrow-deposit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/estimate-of-possible-loss https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/extinguishment-of-debt-amount https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/fair-value-inputs-counterparty-credit-risk https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/fair-value-inputs-discount-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/fair-value-measurement-with-unobservable-inputs-reconciliations-recurring-basis-liability-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/financing-cash-flow https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/financing-receivable-recorded-investment-equal-to-greater-than-90-days-past-due https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/finite-lived-contractual-rights-gross https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/foreign-currency-transaction-gain-loss-unrealized https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/foreign-earnings https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/foreign-earnings-repatriated https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/foreign-pretax-income https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/general-and-administrative-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/goodwill https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/goodwill-acquired https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/goodwill-and-intangible-asset-impairment https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/goodwill-foreign-currency-translation-gain-loss https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/goodwill-translation-adjustments https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/impact-of-restatement-on-earnings-per-share-basic https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/impact-of-restatement-on-earnings-per-share-diluted https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/impairment-of-intangible-assets-excluding-goodwill https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/income-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/income-tax-expense-benefit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/income-tax-expense-benefit-adjustment-of-deferred-tax-asset-liability https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/income-taxes-paid https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-accrued-liabilities-and-other-operating-liabilities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-insurance-settlements-receivable https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-other-noncurrent-liabilities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/increase-decrease-in-restricted-cash-for-operating-activities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/insider-transactions-other https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/insider-transactions-stock-options/purchases https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/insider-transactions-stock-options/sales https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/insider-transactions-stock-units https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/interest-paid https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/inventory https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/inventory-finished-goods-net-of-reserves https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/inventory-raw-materials-net-of-reserves https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/inventory-work-in-process-net-of-reserves https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/inventory-write-down https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/investing-cash-flow https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/late-filing-notices-nt-10-k https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/late-filing-notices-nt-10-q https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/lease-and-rental-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/letters-of-credit-outstanding-amount https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/level-3-liability-gain-loss-included-in-earnings https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/level-3-liability-gain-loss-included-in-other-comprehensive-income https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/level-3-liability-issues https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/liabilities-fair-value-disclosure https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/line-of-credit-facility-amount-outstanding https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/line-of-credit-facility-interest-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/line-of-credit-facility-maximum-borrowing-capacity https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/lines-of-credit-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/loans-and-leases-receivable-allowance https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/long-term-line-of-credit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/maturities-of-available-for-sale-securities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/net-change-in-cash https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/net-income https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/noncurrent-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/notes-and-loans-receivable-net-noncurrent https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/number-of-operating-segments https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-available-for-sale-adjustment-before-reclassification-adjustments-and-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-available-for-sale-adjustment-before-reclassification-adjustments-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-before-reclassifications-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-foreign-currency-transaction-and-translation-gain-loss-before-reclassification-and-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-net-of-tax-2 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-net-of-tax-change https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-reclassification-adjustment-from-aoci-for-sale-of-securities-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-securities-sale-reclassification-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-cash-flow https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-income https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-lease-payments-due https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-lease-payments-due-future-minimum-sublease-rentals https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/other-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/other-income https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/other-noncash-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/other-noncurrent-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/payments-for-postemployment-benefits https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/payments-to-acquire-businesses-gross https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/payments-to-acquire-loans-receivable https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/preferred-shares-facts https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/preferred-stock-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/pretax-income https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/pretax-income-domestic https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/prior-period-reclassification-adjustment https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/proceeds-from-lines-of-credit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/proceeds-from-repayments-of-lines-of-credit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/proceeds-from-repayments-of-restricted-cash-financing-activities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/proceeds-from-sale-and-maturity-of-available-for-sale-securities https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/proceeds-from-sale-of-short-term-investments https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/proceeds-from-short-term-debt https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/product-warranty-accrual https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/property-plant-equipment https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/provision-for-doubtful-accounts https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/provision-for-loan-and-lease-losses https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/public-float https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/receivables-long-term-contracts-or-programs https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/reclassification-from-accumulated-oci-current-period-net-of-tax https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/repayments-of-lines-of-credit https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/research-and-development https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/restricted-cash-and-investments-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/restricted-investments-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/restricted-investments-noncurrent https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/restructuring-and-related-cost-number-of-positions-eliminated https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/restructuring-charges https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/retained-earnings https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/revenue https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sales-revenue-goods-net https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-10-k https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-10-k405 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-10-q https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-15-12g https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-25-nse https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-8-a12g https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-8-k https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-ars https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-ct-order https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-def-14a https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-defa14a https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-defm14a https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-defr14a https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-dfan14a https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-no-act https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-pre-14a https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-prem14a https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/sec-filings-s-2 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-424b2 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-424b3 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-424b4 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-424b7 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-effect https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-rw https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/secondary-offerings-form-s-8-pos https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/selling-and-marketing-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/settlement-agreement-consideration https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/severance-costs https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/severance-costs-1 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/shareholders-equity https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/shares-authorized https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/shares-issued https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/short-term-borrowings https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/short-term-investments https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-based-compensation https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-compensation-cash-received-from-exercise-of-stock-options https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-compensation-tax-benefit-from-compensation-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-compensation-unrecognized-cost https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-issued-shares-issued-for-acquisitions https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-issued-shares-issued-value-share-based-compensation-gross https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-issued-shares-issued-value-stock-options-exercised-net-of-tax-benefit-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-options-vested-in-period-fair-value https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-options-vested-in-period-fair-value-1 https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-repurchase-program-authorized-amount https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/stock-repurchase-program-remaining-authorized-repurchase-amount https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/supplemental-unemployment-benefits-severance-benefits https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/tax-reconciliation-deductions-dividends https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/tax-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/tax-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/tax-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/taxes-payable-current https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/total-assets https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/trading-securities-realized-gain-loss https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-change https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-decrease-from-foreign-currency-translation https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-decrease-from-prior-year-positions https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-increase-from-foreign-currency-translation https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-interest-on-income-taxes-accrued https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-interest-on-income-taxes-expense https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-reduction-from-statute-lapse https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/utb-that-would-impact-effective-tax-rate https://stock.noler.com/us/stock/sciclone-pharmaceuticals-inc/valuation-allowance-deferred-tax-asset-change-in-amount